Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma
| Autor: | Perry Shen, Jonathan C. Hundley, Greg Russell, Edward A. Levine, Samuel P. Jacks |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
medicine.medical_specialty Poor prognosis medicine.medical_treatment Small bowel adenocarcinoma Adenocarcinoma medicine Humans Infusions Parenteral Peritoneal Neoplasms Retrospective Studies Chemotherapy Jejunal Neoplasms business.industry Standard treatment Hyperthermia Induced General Medicine Middle Aged Prognosis medicine.disease Combined Modality Therapy Surgery Peritoneal carcinomatosis Ileal Neoplasms Survival Rate Treatment Outcome Oncology Etiology Peritoneum business Cytoreductive surgery |
| Zdroj: | Journal of Surgical Oncology. 91:112-117 |
| ISSN: | 1096-9098 0022-4790 |
| Popis: | Introduction Peritoneal carcinomatosis (PC) is associated with a dismal prognosis. Small bowel adenocarcinoma is a rare etiology for PC. Due to the rarity, poor prognosis, and lack of standard treatment, we chose to review our experience with this disease process treated with cytoreductive surgery (CS) and intraperitoneal hyperthermic chemotherapy (IPHC). Methods From a prospective database of IPHC patients, six patients diagnosed with PC from adenocarcinoma of the small bowel were identified. Between 1995 and 2004 these patients underwent CS and IPHC with Mitomycin C. A retrospective review was performed on these patients with mortality as the primary outcome measure. Results Three of the six patients in this series are still alive, with a mean follow-up of 19.7 months after treatment with CS and IPHC. Three patients died of disease progression 29, 30, and 45 months after IPHC. Median survival after diagnosis of small bowel adenocarcinoma was 54 months, while median survival after CS and IPHC for PC was 30.1 months. Conclusions Small bowel adenocarcinoma with PC remains an unusual therapeutic challenge. Treatment with CS and IPHC is an attractive option for patients in this setting. J. Surg. Oncol. 2005;91:112–117. © 2005 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text